News

Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe ...
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
Sarepta Therapeutics (NASDAQ:SRPT) resumed its recent sell-off on Thursday after Endpoints News reported that the FDA would ...
Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...
In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The ...
U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators ...
Children’s Hospital Los Angeles paused Sarepta’s Elevidys gene therapy after FDA flagged safety issues, including deaths in ...
A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...
Pharmaceutical Technology on MSN3d

CHMP rejects Elevidys in latest setback for Sarepta

Sarepta said it accepts the CHMP decision on Elevidys, while partner Roche said it will continue working with the EMA.